CSD500 is a unique condom

CSD500 is a condom developed for use by healthy men to help maintain a firm erection whilst wearing a condom. CSD500 is a lubricated condom with a gel Zanifil®, which contains a 1% dose of Glyceryl Trinitrate (GTN) in the teat of a standard latex condom which is absorbed through the penis when the condom is used.

CSD500 has 3 clinically proven claims

  • Increased penile firmness
  • Longer lasting sexual performance
  • Improved sexual performance

Futura to focus resources strategically

  • Approved Class lll Medical Device with ancillary medicinal substance in EU. Approved in Saudi Arabia and other MENA countries.
  • 2 year shelf life recently
    approved -
    R&D now complete.
  • Discussions ongoing with existing and potential partners.
    Non core for Futura.

Significant market potential for the right partner

In 2017, the global condom market was estimated to be worth US$6.8 billion.

Previous research has shown that up to 46% of men have experienced some loss of sensitivity when using a condom during sexual intercourse, which can lead to loss of erection on occasions. This is one reason why some men avoid condoms for either part of or for the duration of sexual intercourse, thereby increasing the risks of unwanted pregnancies and contracting sexually transmitted infections ("STIs").

Futura commissioned a pricing and demand research study by Millward Brown, an internationally respected agency. This research, carried out in the UK and USA, confirmed Futura's confidence in CSD500 as a highly innovative product. The research has been shared with potential licensing partners but the key highlights are:

  • CSD500 can command a price premium over existing condoms
  • CSD500 is expected to gain a market share in excess of 10% in the markets researched with a strong brand

Regulatory and supply chain strategy

Futura has achieved ISO 13485 certification and has established an outsourced supply chain, through TTK Protective Devices Limited ("TTK").

CSD500 is approved by the regulators to be marketed throughout the European Union and a growing number of territories outside of the European Union. The CE mark means that CSD500 can be marketed in all 28 European territories. In addition, a number of other non-European territories also recognise the CE mark process, thereby facilitating registration. Further regulatory approvals have been obtained including several in the Middle East and North Africa (MENA) region - the first approvals for markets outside the EU. Regulatory filings have also been made in further countries.